Forte Biosciences Inc. (Tocagen) (FBRX)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Paul A. Wagner
Employees:
5
4242 CAMPUS POINT COURT, SUITE 500, SAN DIEGO, CA 92121
(858) 412-8400

Forte Biosciences is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.

Data derived from most recent annual or quarterly report
Market Cap 24.139 Million Shares Outstanding23.9 Million Avg 30-day Volume 39.012 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.79
Price to Revenue0.0 Debt to Equity0.0 EBITDA-12.343 Million
Price to Book Value0.4728 Operating Margin0.0 Enterprise Value-23.796 Million
Current Ratio19.448 EPS Growth-1.237 Quick Ratio19.21
1 Yr BETA 1.0802 52-week High/Low 2.97 / 0.9 Profit Margin0.0
Operating Cash Flow Growth47.4849 Altman Z-Score2.9725 Free Cash Flow to Firm -9.381 Million
View SEC Filings from FBRX instead.

View recent insider trading info

Funds Holding FBRX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding FBRX

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-11-14:
    Item 2.02: Results of Operations and Financial Condition
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-15:
    Item 2.02: Results of Operations and Financial Condition
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-12:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-07-12:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-07:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-02:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-05-16:
    Item 2.02: Results of Operations and Financial Condition
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-04-01:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-18:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2021-09-02:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    BRUN SCOTT C.

    • Director
    50,000 2022-11-10 2

    CHEN HUBERT C SEE REMARKS

    • Officer
    0 2022-06-07 2

    FINCK BARBARA K

    • Director
    25,000 2022-06-01 4

    WALKER PATRICIA S

    • Director
    25,000 2022-06-01 2

    DOBERSTEIN STEPHEN K

    • Director
    25,000 2022-06-01 3

    WILLIAMS DONALD ALLEN

    • Director
    25,000 2022-06-01 2

    KORNFELD STEVEN

    • Director
    25,000 2022-06-01 2

    EICHENFIELD LAWRENCE

    • Director
    25,000 2022-06-01 2

    WAGNER PAUL A. SEE REMARKS

    • Officer
    • Director
    135,000 2022-05-12 2

    RILEY ANTONY A CHIEF FINANCIAL OFFICER

    • Officer
    75,000 2022-01-17 1

    DARCY THOMAS E

    • Director
    26,995 2021-01-13 0

    OLIVEIRA STEVEN MICHAEL

    • 10% Owner
    4,139,450 2020-04-14 0

    GRUBER HARRY E PRESIDENT, SCIENCE&INNOVATION

    • Officer
    • Director
    No longer subject to file 2020-02-26 0

    FOLETTA MARK G EVP & CHIEF FINANCIAL OFFICER

    • Officer
    0 2019-10-04 0

    SCHIMMEL PAUL

    • Director
    0 2019-10-04 0

    BERGER FRANKLIN M

    • Director
    0 2019-10-04 0

    DUVALL MARTIN J CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    0 2019-10-04 0

    HASNAIN FAHEEM

    • Director
    0 2019-10-04 0

    PARKINSON DAVID ROSS

    • Director
    0 2019-10-04 0

    KUNKEL LORI ANNE

    • Director
    0 2019-10-04 0

    JOLLY DOUGLAS EVP, RESEARCH & PHARM DEVEL

    • Officer
    0 2019-10-04 0

    KABBINAVAR FAIROOZ SVP CLINICAL DEVELOPMENT

    • Officer
    0 2019-10-04 0

    DAS ASHA SVP & CHIEF MEDICAL OFFICER

    • Officer
    0 2018-03-01 0

    BERMAN DENNIS N

    • FORMER DIRECTOR & OFFICER
    No longer subject to file 2017-04-15 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    BRUN SCOTT C. - Director

    2022-11-14 16:22:06 -0500 2022-11-10 A 50,000 a 50,000 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    FORTE BIOSCIENCES INC FBRX 2022-11-25 22:15:03 UTC 1.553 2.267 1000000
    FORTE BIOSCIENCES INC FBRX 2022-11-25 21:45:04 UTC 1.553 2.267 1000000
    FORTE BIOSCIENCES INC FBRX 2022-11-25 21:15:03 UTC 1.553 2.267 1000000
    FORTE BIOSCIENCES INC FBRX 2022-11-25 20:45:03 UTC 1.553 2.267 1000000
    FORTE BIOSCIENCES INC FBRX 2022-11-25 20:15:03 UTC 1.553 2.267 1000000
    FORTE BIOSCIENCES INC FBRX 2022-11-25 19:45:04 UTC 1.553 2.267 1000000
    FORTE BIOSCIENCES INC FBRX 2022-11-25 19:15:03 UTC 1.553 2.267 1000000
    FORTE BIOSCIENCES INC FBRX 2022-11-25 18:45:03 UTC 1.553 2.267 1000000
    FORTE BIOSCIENCES INC FBRX 2022-11-25 18:15:03 UTC 1.553 2.267 1000000
    FORTE BIOSCIENCES INC FBRX 2022-11-25 17:45:04 UTC 1.553 2.267 1000000
    FORTE BIOSCIENCES INC FBRX 2022-11-25 17:15:03 UTC 1.553 2.267 1000000
    FORTE BIOSCIENCES INC FBRX 2022-11-25 16:45:04 UTC 1.5412 2.2788 1000000
    FORTE BIOSCIENCES INC FBRX 2022-11-25 16:15:03 UTC 1.5412 2.2788 1000000
    FORTE BIOSCIENCES INC FBRX 2022-11-25 15:45:03 UTC 1.5412 2.2788 1000000
    FORTE BIOSCIENCES INC FBRX 2022-11-25 15:15:03 UTC 1.5412 2.2788 1000000
    FORTE BIOSCIENCES INC FBRX 2022-11-25 14:45:04 UTC 1.5412 2.2788 1000000
    FORTE BIOSCIENCES INC FBRX 2022-11-25 14:15:04 UTC 1.5412 2.2788 1000000
    FORTE BIOSCIENCES INC FBRX 2022-11-25 13:45:03 UTC 1.6283 2.1917 1000000
    FORTE BIOSCIENCES INC FBRX 2022-11-25 13:15:03 UTC 1.6283 2.1917 1000000
    FORTE BIOSCIENCES INC FBRX 2022-11-25 12:45:03 UTC 1.6283 2.1917 1000000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments